David R Andes

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6189406/publications.pdf

Version: 2024-02-01

222 papers	26,088 citations	10389 72 h-index	6654 156 g-index
241 all docs	241 docs citations	241 times ranked	18474 citing authors

#	Article	IF	Citations
1	Clinical Practice Guidelines for the Management Candidiasis: 2009 Update by the Infectious Diseases Society of America. Clinical Infectious Diseases, 2009, 48, 503-535.	5.8	2,644
2	Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. Clinical Infectious Diseases, 2016, 62, e1-e50.	5.8	2,489
3	Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. Clinical Infectious Diseases, 2020, 71, 1367-1376.	5.8	1,429
4	Invasive Fungal Infections among Organ Transplant Recipients: Results of the Transplantâ€Associated Infection Surveillance Network (TRANSNET). Clinical Infectious Diseases, 2010, 50, 1101-1111.	5.8	1,281
5	Executive Summary: Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. Clinical Infectious Diseases, 2016, 62, 409-417.	5.8	1,258
6	Prospective Surveillance for Invasive Fungal Infections in Hematopoietic Stem Cell Transplant Recipients, 2001â€“2006: Overview of the Transplantâ€Associated Infection Surveillance Network (TRANSNET) Database. Clinical Infectious Diseases, 2010, 50, 1091-1100.	5.8	1,194
7	Impact of Treatment Strategy on Outcomes in Patients with Candidemia and Other Forms of Invasive Candidiasis: A Patient-Level Quantitative Review of Randomized Trials. Clinical Infectious Diseases, 2012, 54, 1110-1122.	5.8	649
8	A Recently Evolved Transcriptional Network Controls Biofilm Development in Candida albicans. Cell, 2012, 148, 126-138.	28.9	607
9	Critical Role of Bcr1-Dependent Adhesins in C. albicans Biofilm Formation In Vitro and In Vivo. PLoS Pathogens, 2006, 2, e63.	4.7	443
10	Antifungal Therapeutic Drug Monitoring: Established and Emerging Indications. Antimicrobial Agents and Chemotherapy, 2009, 53, 24-34.	3.2	442
11	Pharmacokinetics and pharmacodynamics of antibiotics in otitis media. Pediatric Infectious Disease Journal, 1996, 15, 255-259.	2.0	425
12	Putative Role of Î²-1,3 Glucans in Candida albicans Biofilm Resistance. Antimicrobial Agents and Chemotherapy, 2007, 51, 510-520.	3.2	362
13	In Vivo Pharmacodynamic Activity of Daptomycin. Antimicrobial Agents and Chemotherapy, 2004, 48, 63-68.	3.2	342
14	Epidemiology and Outcomes of Invasive Candidiasis Due to Non-albicans Species of Candida in 2,496 Patients: Data from the Prospective Antifungal Therapy (PATH) Registry 2004â€“2008. PLoS ONE, 2014, 9, e101510.	2.5	338
15	Mechanisms of Candida biofilm drug resistance. Future Microbiology, 2013, 8, 1325-1337.	2.0	317
16	Complementary Adhesin Function in C. albicans Biofilm Formation. Current Biology, 2008, 18, 1017-1024.	3.9	293
17	Biofilm Matrix Regulation by Candida albicans Zap1. PLoS Biology, 2009, 7, e1000133.	5.6	286
18	Factors Associated with Mortality in Transplant Patients with Invasive Aspergillosis. Clinical Infectious Diseases, 2010, 50, 1559-1567.	5.8	269

#	Article	IF	Citations
19	Antifungal Agents. Infectious Disease Clinics of North America, 2016, 30, 51-83.	5.1	264
20	International expert opinion on the management of infection caused by azole-resistant Aspergillus fumigatus. Drug Resistance Updates, 2015, 21-22, 30-40.	14.4	262
21	Pharmacology of Systemic Antifungal Agents. Clinical Infectious Diseases, 2006, 43, S28-S39.	5.8	253
22	A Candida Biofilm-Induced Pathway for Matrix Glucan Delivery: Implications for Drug Resistance. PLoS Pathogens, 2012, 8, e1002848.	4.7	240
23	Novel Entries in a Fungal Biofilm Matrix Encyclopedia. MBio, 2014, 5, e01333-14.	4.1	234
24	Hsp90 Governs Dispersion and Drug Resistance of Fungal Biofilms. PLoS Pathogens, 2011, 7, e1002257.	4.7	231
25	The antimicrobial potential of Streptomyces from insect microbiomes. Nature Communications, 2019, 10, 516.	12.8	222
26	Genetic Basis ofCandidaBiofilm Resistance Due to Drugâ€Sequestering Matrix Glucan. Journal of Infectious Diseases, 2010, 202, 171-175.	4.0	220
27	Protein Binding: Do We Ever Learn?. Antimicrobial Agents and Chemotherapy, 2011, 55, 3067-3074.	3.2	212
28	Synergistic Effect of Calcineurin Inhibitors and Fluconazole against Candida albicans Biofilms. Antimicrobial Agents and Chemotherapy, 2008, 52, 1127-1132.	3.2	205
29	Commensal Protection of Staphylococcus aureus against Antimicrobials by Candida albicans Biofilm Matrix. MBio, 2016, 7, .	4.1	202
30	Fungal Biofilms, Drug Resistance, and Recurrent Infection. Cold Spring Harbor Perspectives in Medicine, 2014, 4, a019729-a019729.	6.2	196
31	Candida albicans biofilm development, modeling a hostâ€“pathogen interaction. Current Opinion in Microbiology, 2006, 9, 340-345.	5.1	190
32	Role of Fks1p and Matrix Glucan in Candida albicans Biofilm Resistance to an Echinocandin, Pyrimidine, and Polyene. Antimicrobial Agents and Chemotherapy, 2010, 54, 3505-3508.	3.2	188
33	Candida albicans biofilmâ€“induced vesicles confer drug resistance through matrix biogenesis. PLoS Biology, 2018, 16, e2006872.	5.6	173
34	Time Course Global Gene Expression Analysis of an In VivoCandidaBiofilm. Journal of Infectious Diseases, 2009, 200, 307-313.	4.0	156
35	In Vivo Pharmacodynamics of Antifungal Drugs in Treatment of Candidiasis. Antimicrobial Agents and Chemotherapy, 2003, 47, 1179-1186.	3.2	154
36	Association of Fluconazole Pharmacodynamics with Mortality in Patients with Candidemia. Antimicrobial Agents and Chemotherapy, 2008, 52, 3022-3028.	3.2	142

#	Article	IF	Citations
37	An expanded regulatory network temporally controls <scp>C</scp>andida albicans biofilm formation. Molecular Microbiology, 2015, 96, 1226-1239.	2.5	140
38	Interface of Candida albicans Biofilm Matrix-Associated Drug Resistance and Cell Wall Integrity Regulation. Eukaryotic Cell, 2011, 10, 1660-1669.	3.4	139
39	Community participation in biofilm matrix assembly and function. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 4092-4097.	7.1	139
40	Development and Validation of an In Vivo Candida albicans Biofilm Denture Model. Infection and Immunity, 2010, 78, 3650-3659.	2.2	138
41	Therapeutic Drug Monitoring of Antifungals: Pharmacokinetic and Pharmacodynamic Considerations. Therapeutic Drug Monitoring, 2008, 30, 167-172.	2.0	136
42	The epidemiology and outcomes of invasive Candida infections among organ transplant recipients in the United States: results of the Transplantâ€Associated Infection Surveillance Network (TRANSNET). Transplant Infectious Disease, 2016, 18, 921-931.	1.7	135
43	Voriconazole Use for Endemic Fungal Infections. Antimicrobial Agents and Chemotherapy, 2009, 53, 1648-1651.	3.2	130
44	Optimizing a Candida Biofilm Microtiter Plate Model for Measurement of Antifungal Susceptibility by Tetrazolium Salt Assay. Journal of Clinical Microbiology, 2011, 49, 1426-1433.	3.9	127
45	Histoplasmosis Complicating Tumor Necrosis Factorâ€"Î± Blocker Therapy: A Retrospective Analysis of 98 Cases. Clinical Infectious Diseases, 2015, 61, 409-417.	5.8	111
46	Bacterial-derived exopolysaccharides enhance antifungal drug tolerance in a cross-kingdom oral biofilm. ISME Journal, 2018, 12, 1427-1442.	9.8	111
47	Comparative Phenotypic Analysis of the Major Fungal Pathogens Candida parapsilosis and Candida albicans. PLoS Pathogens, 2014, 10, e1004365.	4.7	108
48	Candidaâ€"streptococcal interactions in biofilm-associated oral diseases. PLoS Pathogens, 2018, 14, e1007342.	4.7	103
49	In Vivo Pharmacodynamic Activity of the Glycopeptide Dalbavancin. Antimicrobial Agents and Chemotherapy, 2007, 51, 1633-1642.	3.2	102
50	Use of Pharmacokinetic-Pharmacodynamic Analyses To Optimize Therapy with the Systemic Antifungal Micafungin for Invasive Candidiasis or Candidemia. Antimicrobial Agents and Chemotherapy, 2011, 55, 2113-2121.	3.2	102
51	A marine microbiome antifungal targets urgent-threat drug-resistant fungi. Science, 2020, 370, 974-978.	12.6	102
52	Global guideline for the diagnosis and management of the endemic mycoses: an initiative of the European Confederation of Medical Mycology in cooperation with the International Society for Human and Animal Mycology. Lancet Infectious Diseases, The, 2021, 21, e364-e374.	9.1	99
53	Forazolineâ€…A: Marineâ€Derived Polyketide with Antifungal Inâ€…Vivo Efficacy. Angewandte Chemie - International Edition, 2014, 53, 11583-11586.	13.8	98
54	Calcineurin Controls Drug Tolerance, Hyphal Growth, and Virulence in Candida dubliniensis. Eukaryotic Cell, 2011, 10, 803-819.	3.4	97

#	Article	IF	Citations
55	Isavuconazole Concentration in Real-World Practice: Consistency with Results from Clinical Trials. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	94
56	Fungal Super Glue: The Biofilm Matrix and Its Composition, Assembly, and Functions. PLoS Pathogens, 2016, 12, e1005828.	4.7	93
57	Pharmacokinetics and Pharmacodynamics of Antifungals. Infectious Disease Clinics of North America, 2006, 20, 679-697.	5.1	92
58	CNS pharmacokinetics of antifungal agents. Expert Opinion on Drug Metabolism and Toxicology, 2007, 3, 573-581.	3.3	92
59	Activities of Clindamycin, Daptomycin, Doxycycline, Linezolid, Trimethoprim-Sulfamethoxazole, and Vancomycin against Community-Associated Methicillin-Resistant Staphylococcus aureus with Inducible Clindamycin Resistance in Murine Thigh Infection and In Vitro Pharmacodynamic Models. Antimicrobial Agents and Chemotherapy, 2008, 52, 2156-2162.	3.2	91
60	Î²â€1,3 Glucan as a Test for Central Venous Catheter Biofilm Infection. Journal of Infectious Diseases, 2007, 195, 1705-1712.	4.0	85
61	Antifungal Pharmacokinetics and Pharmacodynamics. Cold Spring Harbor Perspectives in Medicine, 2015, 5, a019653-a019653.	6.2	85
62	Optimizing antifungal choice and administration. Current Medical Research and Opinion, 2013, 29, 13-18.	1.9	83
63	Pharmacodynamic Target Evaluation of a Novel Oral Glucan Synthase Inhibitor, SCY-078 (MK-3118), Using an In Vivo Murine Invasive Candidiasis Model. Antimicrobial Agents and Chemotherapy, 2015, 59, 1265-1272.	3.2	83
64	Core Recommendations for Antifungal Stewardship: A Statement of the Mycoses Study Group Education and Research Consortium. Journal of Infectious Diseases, 2020, 222, S175-S198.	4.0	83
65	Methodologies for in vitro and in vivo evaluation of efficacy of antifungal and antibiofilm agents and surface coatings against fungal biofilms. Microbial Cell, 2018, 5, 300-326.	3.2	81
66	Application of pharmacokinetics and pharmacodynamics to antimicrobial therapy of respiratory tract infections. Clinics in Laboratory Medicine, 2004, 24, 477-502.	1.4	79
67	Phaeohyphomycosis in transplant recipients: Results from the Transplant Associated Infection Surveillance Network (TRANSNET). Medical Mycology, 2015, 53, 440-446.	0.7	79
68	Dual action antifungal small molecule modulates multidrug efflux and TOR signaling. Nature Chemical Biology, 2016, 12, 867-875.	8.0	79
69	Animal models in the pharmacokinetic/pharmacodynamic evaluation of antimicrobial agents. Bioorganic and Medicinal Chemistry, 2016, 24, 6390-6400.	3.0	79
70	Isavuconazole (BAL4815) Pharmacodynamic Target Determination in an In Vivo Murine Model of Invasive Pulmonary Aspergillosis against Wild-Type and cyp51 Mutant Isolates of Aspergillus fumigatus. Antimicrobial Agents and Chemotherapy, 2013, 57, 6284-6289.	3.2	78
71	Regulatory Role of Glycerol in Candida albicans Biofilm Formation. MBio, 2013, 4, e00637-12.	4.1	77
72	Conserved and Divergent Roles of Bcr1 and CFEM Proteins in Candida parapsilosis and Candida albicans. PLoS ONE, 2011, 6, e28151.	2.5	76

#	Article	IF	Citations
73	A Dualâ€Responsive Antibioticâ€Loaded Nanoparticle Specifically Binds Pathogens and Overcomes Antimicrobialâ€Resistant Infections. Advanced Materials, 2021, 33, e2006772.	21.0	76
74	Exposure-Response Relationships for Isavuconazole in Patients with Invasive Aspergillosis and Other Filamentous Fungi. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	75
75	Nontoxic antimicrobials that evade drug resistance. Nature Chemical Biology, 2015, 11, 481-487.	8.0	74
76	In Vivo Pharmacokinetics and Pharmacodynamics of ZTI-01 (Fosfomycin for Injection) in the Neutropenic Murine Thigh Infection Model against Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	71
77	A Histone Deacetylase Complex Mediates Biofilm Dispersal and Drug Resistance in Candida albicans. MBio, 2014, 5, e01201-14.	4.1	70
78	Comparative analysis ofCandidabiofilm quantitation assays. Medical Mycology, 2012, 50, 214-218.	0.7	69
79	Posaconazole Pharmacodynamic Target Determination against Wild-Type and Cyp51 Mutant Isolates of Aspergillus fumigatus in an In Vivo Model of Invasive Pulmonary Aspergillosis. Antimicrobial Agents and Chemotherapy, 2013, 57, 579-585.	3.2	68
80	Use of Pharmacodynamic Indices To Predict Efficacy of Combination Therapy In Vivo. Antimicrobial Agents and Chemotherapy, 1999, 43, 2473-2478.	3.2	66
81	Pharmacodynamic Optimization for Treatment of Invasive Candida auris Infection. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	65
82	Global Identification of Biofilm-Specific Proteolysis in Candida albicans. MBio, 2016, 7, .	4.1	63
83	Loss of CclA, required for histone 3 lysine 4 methylation, decreases growth but increases secondary metabolite production inAspergillus fumigatus. PeerJ, 2013, 1, e4.	2.0	63
84	Reduced Biocide Susceptibility in Candida albicans Biofilms. Antimicrobial Agents and Chemotherapy, 2008, 52, 3411-3413.	3.2	61
85	Host Contributions to Construction of Three Device-Associated Candida albicans Biofilms. Infection and Immunity, 2015, 83, 4630-4638.	2.2	58
86	Contributions of the Biofilm Matrix to Candida Pathogenesis. Journal of Fungi (Basel, Switzerland), 2020, 6, 21.	3.5	58
87	Candida albicans FRE8 encodes a member of the NADPH oxidase family that produces a burst of ROS during fungal morphogenesis. PLoS Pathogens, 2017, 13, e1006763.	4.7	57
88	Pharmacodynamics of Fluoroquinolones in Experimental Models of Endocarditis. Clinical Infectious Diseases, 1998, 27, 47-50.	5.8	56
89	In Vivo Pharmacokinetics and Pharmacodynamics of APX001 against Candida spp. in a Neutropenic Disseminated Candidiasis Mouse Model. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	56
90	Pharmacodynamic Evaluation of Rezafungin (CD101) against Candida auris in the Neutropenic Mouse Invasive Candidiasis Model. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	56

#	Article	IF	Citations
91	MSG-10: a Phase 2 study of oral ibrexafungerp (SCY-078) following initial echinocandin therapy in non-neutropenic patients with invasive candidiasis. Journal of Antimicrobial Chemotherapy, 2019, 74, 3056-3062.	3.0	54
92	Transcriptional rewiring over evolutionary timescales changes quantitative and qualitative properties of gene expression. ELife, 2016, 5, .	6.0	54
93	Isavuconazole Pharmacodynamic Target Determination for Candida Species in an In Vivo Murine Disseminated Candidiasis Model. Antimicrobial Agents and Chemotherapy, 2013, 57, 5642-5648.	3.2	52
94	The Extracellular Matrix of Fungal Biofilms. Advances in Experimental Medicine and Biology, 2016, 931, 21-35.	1.6	52
95	Conservation and Divergence in the Candida Species Biofilm Matrix Mannan-Glucan Complex Structure, Function, and Genetic Control. MBio, 2018, 9, .	4.1	52
96	Comparison of In Vitro Susceptibility Characteristics of Candida Species from Cases of Invasive Candidiasis in Solid Organ and Stem Cell Transplant Recipients: Transplant-Associated Infections Surveillance Network (TRANSNET), 2001 to 2006. Journal of Clinical Microbiology, 2011, 49, 2404-2410.	3.9	51
97	A small molecule produced by Lactobacillus species blocks Candida albicans filamentation by inhibiting a DYRK1-family kinase. Nature Communications, 2021, 12, 6151.	12.8	50
98	Comparative Pharmacodynamics of the New Oxazolidinone Tedizolid Phosphate and Linezolid in a Neutropenic Murine Staphylococcus aureus Pneumonia Model. Antimicrobial Agents and Chemotherapy, 2012, 56, 5916-5922.	3.2	49
99	Fungal Biofilms: In Vivo Models for Discovery of Anti-Biofilm Drugs. Microbiology Spectrum, 2015, 3, .	3.0	49
100	An oxindole efflux inhibitor potentiates azoles and impairs virulence in the fungal pathogen Candida auris. Nature Communications, 2020, 11, 6429.	12.8	49
101	Fungal Sepsis: Optimizing Antifungal Therapy in the Critical Care Setting. Critical Care Clinics, 2011, 27, 123-147.	2.6	48
102	Inoculum Effects of Ceftobiprole, Daptomycin, Linezolid, and Vancomycin with Staphylococcus aureus and Streptococcus pneumoniae at Inocula of 10 ⁵ and 10 ⁷ CFU Injected into Opposite Thighs of Neutropenic Mice. Antimicrobial Agents and Chemotherapy, 2013, 57, 1434-1441.	3.2	48
103	Variability and exposureâ€“response relationships of isavuconazole plasma concentrations in the Phase 3 SECURE trial of patients with invasive mould diseases. Journal of Antimicrobial Chemotherapy, 2019, 74, 761-767.	3.0	48
104	Pharmacodynamics of a Long-Acting Echinocandin, CD101, in a Neutropenic Invasive-Candidiasis Murine Model Using an Extended-Interval Dosing Design. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	48
105	Drug-Drug Interaction Associated with Mold-Active Triazoles among Hospitalized Patients. Antimicrobial Agents and Chemotherapy, 2016, 60, 3398-3406.	3.2	45
106	In Vivo Pharmacodynamic Target Assessment of Delafloxacin against Staphylococcus aureus, Streptococcus pneumoniae, and Klebsiella pneumoniae in a Murine Lung Infection Model. Antimicrobial Agents and Chemotherapy, 2016, 60, 4764-4769.	3.2	44
107	The synthesis of indolo[2,3-b]quinoline derivatives with a guanidine group: Highly selective cytotoxic agents. European Journal of Medicinal Chemistry, 2015, 105, 208-219.	5.5	43
108	In vivo infection models in the pre-clinical pharmacokinetic/pharmacodynamic evaluation of antimicrobial agents. Current Opinion in Pharmacology, 2017, 36, 94-99.	3.5	42

#	Article	IF	Citations
109	Coordination of fungal biofilm development by extracellular vesicle cargo. Nature Communications, 2021, 12, 6235.	12.8	42
110	Clinical utility of antifungal pharmacokinetics and pharmacodynamics. Current Opinion in Infectious Diseases, 2004, 17, 533-540.	3.1	41
111	Modelâ€Informed Drug Development for Antiâ€Infectives: State of the Art and Future. Clinical Pharmacology and Therapeutics, 2021, 109, 867-891.	4.7	41
112	Bypass of Candida albicans Filamentation/Biofilm Regulators through Diminished Expression of Protein Kinase Cak1. PLoS Genetics, 2016, 12, e1006487.	3.5	39
113	Optimizing Echinocandin Dosing and Susceptibility Breakpoint Determination via In Vivo Pharmacodynamic Evaluation against Candida glabrata with and without fks Mutations. Antimicrobial Agents and Chemotherapy, 2012, 56, 5875-5882.	3.2	38
114	Rat Indwelling Urinary Catheter Model of Candida albicans Biofilm Infection. Infection and Immunity, 2014, 82, 4931-4940.	2.2	38
115	In Vivo Pharmacodynamic Evaluation of Omadacycline (PTK 0796) against Streptococcus pneumoniae in the Murine Pneumonia Model. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	37
116	We can do better: a fresh look at echinocandin dosing. Journal of Antimicrobial Chemotherapy, 2018, 73, i44-i50.	3.0	37
117	APX001 Pharmacokinetic/Pharmacodynamic Target Determination against Aspergillus fumigatus in an In Vivo Model of Invasive Pulmonary Aspergillosis. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	37
118	Topical delivery of ebselen encapsulated in biopolymeric nanocapsules: drug repurposing enhanced antifungal activity. Nanomedicine, 2018, 13, 1139-1155.	3.3	36
119	In Vivo Pharmacodynamic Target Assessment of Eravacycline against Escherichia coli in a Murine Thigh Infection Model. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	35
120	Biomineral armor in leaf-cutter ants. Nature Communications, 2020, 11, 5792.	12.8	34
121	In Vivo Pharmacokinetics and Pharmacodynamics of the Lantibiotic NAI-107 in a Neutropenic Murine Thigh Infection Model. Antimicrobial Agents and Chemotherapy, 2015, 59, 1258-1264.	3.2	32
122	How Clean Is the Linen at My Hospital? The Mucorales on Unclean Linen Discovery Study of Large United States Transplant and Cancer Centers. Clinical Infectious Diseases, 2019, 68, 850-853.	5.8	31
123	Novel approaches for the treatment of methicillin-resistant Staphylococcus aureus: Using nanoparticles to overcome multidrug resistance. Drug Discovery Today, 2021, 26, 31-43.	6.4	30
124	Impact of In Vivo Triazole and Echinocandin Combination Therapy for Invasive Pulmonary Aspergillosis: Enhanced Efficacy against Cyp51 Mutant Isolates. Antimicrobial Agents and Chemotherapy, 2013, 57, 5438-5447.	3.2	29
125	Searching for new derivatives of neocryptolepine: Synthesis, antiproliferative, antimicrobial and antifungal activities. European Journal of Medicinal Chemistry, 2014, 78, 304-313.	5.5	29
126	Intraluminal Release of an Antifungal Î²-Peptide Enhances the Antifungal and Anti-Biofilm Activities of Multilayer-Coated Catheters in a Rat Model of Venous Catheter Infection. ACS Biomaterials Science and Engineering, 2016, 2, 112-121.	5.2	29

#	Article	IF	Citations
127	Turbinmicin inhibits Candida biofilm growth by disrupting fungal vesicleâ€“mediated trafficking. Journal of Clinical Investigation, 2021, 131, .	8.2	29
128	Clinical Pharmacodynamic Index Identification for Micafungin in Esophageal Candidiasis: Dosing Strategy Optimization. Antimicrobial Agents and Chemotherapy, 2013, 57, 5714-5716.	3.2	28
129	Pleiotropic effects of the vacuolar ABC transporter MLT1 of Candida albicans on cell function and virulence. Biochemical Journal, 2016, 473, 1537-1552.	3.7	28
130	Clinical pharmacodynamics of antifungals. Infectious Disease Clinics of North America, 2003, 17, 635-649.	5.1	27
131	Pyonitrins Aâ€“D: Chimeric Natural Products Produced by Pseudomonas protegens. Journal of the American Chemical Society, 2019, 141, 17098-17101.	13.7	27
132	Large-scale production and isolation of Candida biofilm extracellular matrix. Nature Protocols, 2016, 11, 2320-2327.	12.0	26
133	Pharmacological Basis of CD101 Efficacy: Exposure Shape Matters. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	26
134	In Vivo Pharmacodynamics of Omadacycline against Staphylococcus aureus in the Neutropenic Murine Thigh Infection Model. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	26
135	Evolution of the complex transcription network controlling biofilm formation in Candida species. ELife, 2021, 10, .	6.0	25
136	Pharmacodynamic Evaluation of MRX-8, a Novel Polymyxin, in the Neutropenic Mouse Thigh and Lung Infection Models against Gram-Negative Pathogens. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	24
137	Specialized Metabolites Reveal Evolutionary History and Geographic Dispersion of a Multilateral Symbiosis. ACS Central Science, 2021, 7, 292-299.	11.3	23
138	Antifungal PK/PD Considerations in Fungal Pulmonary Infections. Seminars in Respiratory and Critical Care Medicine, 2011, 32, 783-794.	2.1	22
139	Comparative Pharmacodynamics of Telavancin and Vancomycin in the Neutropenic Murine Thigh and Lung Infection Models against Staphylococcus aureus. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	22
140	The Candida albicans biofilm gene circuit modulated at the chromatin level by a recent molecular histone innovation. PLoS Biology, 2019, 17, e3000422.	5.6	22
141	Use of an Animal Model of Disseminated Candidiasis in the Evaluation of Antifungal Therapy. , 2005, 118, 111-128.		21
142	Targeting fungal membrane homeostasis with imidazopyrazoindoles impairs azole resistance and biofilm formation. Nature Communications, 2022, 13, .	12.8	21
143	In vivopharmacodynamics of lefamulin, the first systemic pleuromutilin for human use, in a neutropenic murine thigh infection model. Journal of Antimicrobial Chemotherapy, 2019, 74, iii5-iii10.	3.0	20
144	Outcomes by MIC Values for Patients Treated with Isavuconazole or Voriconazole for Invasive Aspergillosis in the Phase 3 SECURE and VITAL Trials. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	20

#	Article	IF	Citations
145	Application of 3D NMR for Structure Determination of Peptide Natural Products. Journal of Organic Chemistry, 2015, 80, 8713-8719.	3.2	19
146	Targeting Fibronectin To Disrupt In Vivo Candida albicans Biofilms. Antimicrobial Agents and Chemotherapy, 2016, 60, 3152-3155.	3.2	18
147	The protein kinase Ire1 impacts pathogenicity of <scp> Candida albicans </scp> by regulating homeostatic adaptation to endoplasmic reticulum stress. Cellular Microbiology, 2021, 23, e13307.	2.1	18
148	Antifungal pharmacokinetics and pharmacodynamics: understanding the implications for antifungal drug resistance. Drug Resistance Updates, 2004, 7, 185-194.	14.4	17
149	Modeling of Fungal Biofilms Using a Rat Central Vein Catheter. Methods in Molecular Biology, 2012, 845, 547-556.	0.9	17
150	Insights into fungal pathogenesis from the iatrogenic epidemic of Exserohilum rostratum fungal meningitis. Fungal Genetics and Biology, 2013, 61, 143-145.	2.1	17
151	WCK 5222 (Cefepime-Zidebactam) Pharmacodynamic Target Analysis against Metallo-Î²-Lactamase-Producing Enterobacteriaceae in the Neutropenic Mouse Pneumonia Model. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	17
152	Distinct roles of the 7-transmembrane receptor protein Rta3 in regulating the asymmetric distribution of phosphatidylcholine across the plasma membrane and biofilm formation inCandida albicans. Cellular Microbiology, 2017, 19, e12767.	2.1	16
153	Impact of Triazole Therapeutic Drug Monitoring Availability and Timing. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	16
154	Determination of Pharmacodynamic Target Exposures for Rezafungin against Candida tropicalis and Candida dubliniensis in the Neutropenic Mouse Disseminated Candidiasis Model. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	16
155	Bacterial Infections in the Stem Cell Transplant Recipient and Hematologic Malignancy Patient. Infectious Disease Clinics of North America, 2019, 33, 399-445.	5.1	16
156	Chemical Exchanges between Multilateral Symbionts. Organic Letters, 2021, 23, 1648-1652.	4.6	16
157	Pharmacokinetics and Pharmacodynamics of?Tetracyclines. Infectious Disease and Therapy, 2007, , 267-278.	0.0	16
158	Preventing Pseudomonas aeruginosa Biofilms on Indwelling Catheters by Surface-Bound Enzymes. ACS Applied Bio Materials, 2021, 4, 8248-8258.	4.6	16
159	Exploiting the vulnerable active site of a copper-only superoxide dismutase to disrupt fungal pathogenesis. Journal of Biological Chemistry, 2019, 294, 2700-5412.	3.4	15
160	Pharmacokinetic/Pharmacodynamic Evaluation of a Novel Aminomethylcycline Antibiotic, KBP-7072, in the Neutropenic Murine Pneumonia Model against Staphylococcus aureus and Streptococcus pneumoniae. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	15
161	The Role of In Vitro Susceptibility Testing in the Management of Candida and Aspergillus. Journal of Infectious Diseases, 2017, 216, S452-S457.	4.0	14
162	In Vivo Pharmacodynamic Evaluation of an FtsZ Inhibitor, TXA-709, and Its Active Metabolite, TXA-707, in a Murine Neutropenic Thigh Infection Model. Antimicrobial Agents and Chemotherapy, 2015, 59, 6568-6574.	3.2	13

#	Article	IF	Citations
163	Achievement of clinical isavuconazole blood concentrations in transplant recipients with isavuconazonium sulphate capsules administered via enteral feeding tube. Journal of Antimicrobial Chemotherapy, 2020, 75, 3023-3028.	3.0	13
164	Editorial Commentary: Antifungal Therapeutic Drug Monitoring Progress: Getting It Right the First Time. Clinical Infectious Diseases, 2012, 55, 391-393.	5.8	12
165	Antifungal Efficacy of an Intravenous Formulation Containing Monomeric Amphotericin B, 5-Fluorocytosine, and Saline for Sodium Supplementation. Pharmaceutical Research, 2017, 34, 1115-1124.	3.5	12
166	A targeted fungal prophylaxis protocol with static dosed fluconazole significantly reduces invasive fungal infection after liver transplantation. Transplant Infectious Disease, 2019, 21, e13156.	1.7	11
167	In Vivo Pharmacodynamic Characterization of a Novel Odilorhabdin Antibiotic, NOSO-502, against Escherichia coli and Klebsiella pneumoniae in a Murine Thigh Infection Model. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	9
168	In Vivo Pharmacodynamic Target Determination for Delafloxacin against Klebsiella pneumoniae and Pseudomonas aeruginosa in the Neutropenic Murine Pneumonia Model. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	9
169	Folate Functionalized Lipid Nanoparticles for Targeted Therapy of Methicillin-Resistant Staphylococcus aureus. Pharmaceutics, 2021, 13, 1791.	4.5	9
170	Continuous flow synthesis and antimicrobial evaluation of NHC* silver carboxylate derivatives of SBC3 in vitro and in vivo. Metallomics, 2021, 13, .	2.4	9
171	Pharmacokinetics and pharmacodynamics in the development of antifungal compounds. Current Opinion in Investigational Drugs, 2003, 4, 991-8.	2.3	9
172	Pharmacokineticsâ€“pharmacodynamics, computer decision support technologies, and antimicrobial stewardship: the compass and rudder. Diagnostic Microbiology and Infectious Disease, 2018, 91, 371-382.	1.8	8
173	In Vivo Pharmacodynamic Evaluation of Omadacycline against Staphylococcus aureus in the Neutropenic Mouse Pneumonia Model. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	8
174	Old In Vitro Antimicrobial Breakpoints Are Misleading Stewardship Efforts, Delaying Adoption of Innovative Therapies, and Harming Patients. Open Forum Infectious Diseases, 2020, 7, ofaa084.	0.9	8
175	The Role of Second-Generation Antifungal Triazoles for Treatment of the Endemic Mycoses. Current Infectious Disease Reports, 2010, 12, 471-478.	3.0	7
176	Identification of the In Vivo Pharmacokinetics and Pharmacodynamic Driver of Iclaprim. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	7
177	Small-Molecule Morphogenesis Modulators Enhance the Ability of 14-Helical Î²-Peptides To Prevent Candida albicans Biofilm Formation. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	7
178	Managing uncertainty in antifungal dosing: antibiograms, therapeutic drug monitoring and drug-drug interactions. Current Opinion in Infectious Diseases, 2021, 34, 288-296.	3.1	7
179	Genome Mining and Metabolomics Unveil Pseudonochelin: A Siderophore Containing 5-Aminosalicylate from a Marine-Derived Pseudonocardia sp. Bacterium. Organic Letters, 2022, 24, 3998-4002.	4.6	7
180	Development of New Strategies for Echinocandins: Progress in Translational Research. Clinical Infectious Diseases, 2015, 61, S601-S603.	5.8	6

#	Article	IF	Citations
181	The Role of New Posaconazole Formulations in the Treatment of Candida albicans Infections: Data from an In Vitro Pharmacokinetic-Pharmacodynamic Model. Antimicrobial Agents and Chemotherapy, 2021, 65, .	3.2	6
182	Formation and characterization of biofilms formed by salt-tolerant yeast strains in seawater-based growth medium. Applied Microbiology and Biotechnology, 2021, 105, 2411-2426.	3.6	5
183	Review of techniques for diagnosis of catheter-related Candida biofilm infections. Current Fungal Infection Reports, 2008, 2, 237-243.	2.6	4
184	Candida Biofilm Tolerance: Comparison of Planktonic and Biofilm Resistance Mechanisms. , 2017, , 77-92.		4
185	Characterization of an Uncinocarpus reesii-expressed recombinant tube precipitin antigen of Coccidioides posadasii for serodiagnosis. PLoS ONE, 2019, 14, e0221228.	2.5	4
186	Pharmacokinetic/Pharmacodynamic Evaluation of Solithromycin against Streptococcus pneumoniae Using Data from a Neutropenic Murine Lung Infection Model. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	4
187	Has the Optimal Therapy for Invasive Candidiasis Now Been Defined?. Clinical Infectious Diseases, 2019, 68, 1990-1992.	5.8	4
188	Toward Harmonization of Voriconazole CLSI and EUCAST Breakpoints for Candida albicans Using a Validated In Vitro Pharmacokinetic/Pharmacodynamic Model. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	4
189	Implementation of telehealth antimicrobial stewardship through partnership of an academic medical center and a community hospital. American Journal of Health-System Pharmacy, 2021, 78, 2256-2264.	1.0	4
190	Preparation of Candida albicans Biofilms for Transmission Electron Microscopy. Bio-protocol, 2013, 3, .	0.4	4
191	A Label-Free Cellular Proteomics Approach to Decipher the Antifungal Action of DiMIQ, a Potent Indolo[2,3-b]Quinoline Agent, against Candida albicans Biofilms. International Journal of Molecular Sciences, 2021, 22, 108.	4.1	4
192	Antifungal Pharmacokinetics and Pharmacodynamics. , 2011, , 121-134.		3
193	Fungal Biofilms:In VivoModels for Discovery of Anti-Biofilm Drugs. , 2015, , 33-49.		3
194	Traditional PK-PD Indices for Efficacy â€“ Can We Do Better?. Open Forum Infectious Diseases, 2017, 4, S298-S298.	0.9	3
195	Antifungals: Drug Class, Mechanisms of Action, Pharmacokinetics/Pharmacodynamics, Drug-Drug Interactions, Toxicity, and Clinical Use. , 0, , 343-371.		3
196	Preparation of Candida albicans Biofilms Using an in vivo Rat Central Venous Catheter Model. Bio-protocol, 2013, 3, .	0.4	3
197	Animal Models to Evaluate Anti-infective Pharmacodynamics. Methods in Pharmacology and Toxicology, 2016, , 59-87.	0.2	2
198	The Role of Biofilm Matrix in Mediating Antifungal Resistance. , 2017, , 369-384.		2

#	Article	IF	Citations
199	Regulatory Level of Evidence and Practicality in Antifungal Use Decisions for Less Common Fungal Diseases. Clinical Infectious Diseases, 2021, , .	5.8	2
200	Contributions of Extracellular Vesicles to Fungal Biofilm Pathogenesis. Current Topics in Microbiology and Immunology, 2021, 432, 67-79.	1.1	2
201	Race and invasive fungal infection in solid organ transplant recipients. Ethnicity and Disease, 2014, 24, 382-5.	2.3	2
202	Polymeric Micelles for the Delivery of Polyene Antibiotics. ACS Symposium Series, 2006, , 14-26.	0.5	1
203	Pharmacodynamics of antifungal drugs: A strategy to optimize efficacy. Current Fungal Infection Reports, 2008, 2, 12-19.	2.6	1
204	Antifungal therapy: current concepts and evidence-based management. Current Medical Research and Opinion, 2013, 29, 289-290.	1.9	1
205	Reply to Oude Lashof and Vogelaers. Clinical Infectious Diseases, 2013, 56, 1515-1516.	5.8	1
206	Pharmacodynamics of Quinolone Antimicrobial Agents. , 2014, , 147-155.		1
207	Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses for Delafloxacin to Provide Dose Selection Support for the Treatment of Patients With Community-Acquired Bacterial Pneumonia (CABP). Open Forum Infectious Diseases, 2016, 3, .	0.9	1
208	Pharmacodynamic Optimization for the Treatment of Invasive Candida auris Infection. Open Forum Infectious Diseases, 2017, 4, S73-S73.	0.9	1
209	1389. Pharmacokinetic/Pharmacodynamic (PK/PD) Evaluation of a Novel Aminomethylcycline Antibiotic, KBP-7072, in the Neutropenic Murine Pneumonia Model Against S. aureus (SA) and S. pneumoniae (SPN). Open Forum Infectious Diseases, 2018, 5, S426-S426.	0.9	1
210	Candidemia in the Growing Opioid Epidemic: A Distinct and Emerging Entity. Clinical Infectious Diseases, 2020, 71, 1738-1740.	5.8	1
211	Pyridine-2,6-Dithiocarboxylic Acid and Its Metal Complexes: New Inhibitors of New Delhi Metallo -Lactamase-1. Marine Drugs, 2020, 18, 295.	4.6	1
212	Azoles. , 2011, , 61-93.		1
213	Imaging of the Development and Therapeutic Response of an In Vivo Fungal Catheter Biofilm. Microscopy Today, 2005, 13, 30-33.	0.3	0
214	The Microbe-Host Interface in Respiratory Tract Infections Edited by Jan L. L. Kimpen and Octavio Ramilo Wymondham, UK: Horizon Bioscience, 2005. 323 pp., illustrated. $139.95 (cloth). Clinical Infectious Diseases, 2005, 41, 767-768.	5.8	0
215	Comparative In Vivo Pharmacokinetics/Pharmacodynamics of Telavancin and Vancomycin in the Neutropenic Murine Thigh Infection Model Against Staphylococcus aureus. Open Forum Infectious Diseases, 2016, 3, .	0.9	0
216	Antifungal Pharmacokinetics and Pharmacodynamics. Methods in Pharmacology and Toxicology, 2016, , 369-383.	0.2	0

#	Article	IF	Citations
217	In Vivo Candida Device Biofilm Models. , 2017, , 93-113.		0
218	Breaking New Ground: An Evaluation of Susceptibility Breakpoints for Echinocandins against Candida Species. Open Forum Infectious Diseases, 2017, 4, S298-S298.	0.9	0
219	Echinocandins. , 2021, , 438-448.		0
220	Treatment of Community-Acquired Respiratory Tract Infections with Other Antibiotics. , 2003, , 145-153.		0
221	Antifungal Agents Pharmacokinetics and ÂPharmacodynamics of Amphotericin B. Infectious Disease and Therapy, 2007, , 315-326.	0.0	0
222	The Role of Biofilm Matrix in Mediating Antifungal Resistance. , 2014, , 1-14.		0